Synairgen Share Discussion Threads

[makendon] 09/4/2020 22:11

Credit to John117 on LSE

www.pharmaceutical-journal.com/news-and-analysis/features/the-hunt-for-an-effective-treatment-for-covid-19/20207883.article?firstPass=false

And this one...

www.finncap.com/news-events/global-pharma-and-biotechs-fight-against-covid-19

Perhaps it’s time for some good news. First of all, just today biotherapeutics developer Avacta has announced its partnership with Cytiva, formerly known as GE Healthcare Life Sciences, to develop and manufacture a point-of-care (POC) rapid test to diagnose COVID-19 infection.

Things are moving exceptionally fast in the pharma and biotech fight against COVID-19.

Meanwhile, we recently helped raise £14m for drug discovery and development firm Synairgen. The funding will be used by the firm to conduct a vital phase II clinical trial of its candidate SNG001 in COVID-19 patients – a trial that received expedited approval by UK authorities and within days of the fundraise has already dosed its first patient.

Our clients Avacta and Synairgen are not the only protagonists in this rapidly evolving story. Things are moving exceptionally fast in the pharma and biotech fight against COVID-19.

Firstly, the pharma side. With regulatory approvals getting rushed through as with Synairgen’s candidate, naturally, our attention turned to some of the other drug development programmes on the radar.

To caveat, while companies are working on a vaccine for COVID-19, these could take 12-18 months to arrive, if they arrive at all. Nevertheless, in the shorter-term, companies and institutions are fast-tracking investigation and development of therapies to treat COVID-19 and its associated complications.

Never before has the academic world and industry mobilised together in such a manner

SNG001 (Inhaled interferon beta – Synairgen)

Synairgen’s SNG001 is a formulation of interferon beta for direct delivery to the lungs via nebulisation. A double-blind, placebo-controlled trial of SNG001 in mild-moderate COVID-19 patients began in late March. It has been found that the addition of exogenous IFN-beta before or during viral infection of lung cells can either prevent or greatly diminish cell damage and viral replication, respectively.

SNG001 was identified in the WHO’s landscape analysis of therapeutics on 17 February 2020 as the only Phase II/III observational therapy delivered by the inhaled route. finnCap helped Synairgen raise £14m at the end of March and those funds will be used to fund the trial activity, manufacture SNG001 and also for working capital requirements.

[the patient investor] 09/4/2020 22:05

makendon
Yes, Bergamo is a very beautiful city, I do not know Brescia. Badly hit area indeed.

[makendon] 09/4/2020 20:52

TPI, haha good one. I spent half of last year in Bergamo & Brescia on business, love the place. Such a shame covid attacked there so significantly

[peachie 74] 09/4/2020 20:17

Christ. It’s almost worth driving down to Southampton and asking directly !

[the patient investor] 09/4/2020 19:49

re nurse

scrolling down, no news

[the patient investor] 09/4/2020 19:40

makendon

ah! I am Italian but I will surprise you because I know who the Geordies are.
Best people! I had a fabulous girlfriend from Newcastle and many friends too, fantastic people. I know that you thrive on understatements!

[nobbygnome] 09/4/2020 19:40

Has the clinical trial nurse at Southampton tweeted any more info about the trial? I suspect she has been told to stop giving out confidential information...

[the patient investor] 09/4/2020 19:36

Just watch what he does and recommends and....do the opposite. :-)


you cannot go wrong, sadly it is true

[nobbygnome] 09/4/2020 19:35

Well if they get out of intensive care and hospital quicker because their condition improves, then they will use less oxygen.

[harrythehorse] 09/4/2020 19:29

Nobody's answered my question re oxygen 3138, is that because no one knows or was it a stupid question? If so please tell me, I can take it!

[wetdream] 09/4/2020 19:20

Looks like about 1m shares reported after the close.

[makendon] 09/4/2020 19:11

>>TPI Re 3171,

That’s just typical geordie humour my friend. The weekend is long enough to forget today’s debacle, looking forward to a positive Tuesday

[dovey21] 09/4/2020 18:16

I got the same treatment this morning. Water off a ducks back. :-)..unlike him, I've had a great week.. Top sliced some good profits and heavy here with the expectation to take some good profits in the coming week(s). Just watch what he does and recommends and....do the opposite. :-)

[half full or half empty] 09/4/2020 17:57

On the LSE board they are showing as trades form yesterday. One from the morning, and one from near the end of yesterday.

[makendon] 09/4/2020 17:49

Some strange after hours transactions (?) gone through:

Num: 1095 - 50.41p - 50,000

Num: 1093 - 51.75p - 100,000

At no point today was the share price anywhere near that for buy or sell

Anyone have an idea how that happens?

[the patient investor] 09/4/2020 17:27

400p by xmas

[the patient investor] 09/4/2020 17:27

8017102459

NCYT ‘chief ramper’?? I didn’t notice!!


lol




So much for Likya’s recurring pattern & blue finish.
double lol

[141jaffa] 09/4/2020 17:21

Noticed that beta interferon has been removed from the Recovery Trial website as the 4th on that list and replaced with Azithromycin. There is a subsequent protocol update on the site too as of today.

I know SNG001 wasn't in this trial anyway, ( but was on that list for some odd reason ??? ) ........so Im hoping that its removal today is just tidying up /clarification, not anything else. Any views ?

[langland] 09/4/2020 16:48

NG,

Did you look at EVG and lung suppression. I doubt there is any mileage in it but you could have a look. The MOA for sulfurophane does not look appropriate.

[dave444] 09/4/2020 16:45

I think it will fall back next week while some of the share placing hit the market from Wednesday onwards and then once worked through resume an upward track